我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

左西孟旦治疗心血管危重症的临床研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第1期
页码:
113-116
栏目:
综述
出版日期:
2017-10-10

文章信息/Info

Title:
Clinical research progress of levosimendan in cardiovascular critical illness
作者:
陈永清1; 蔡晓庆1; 胡 威1; 温 晋2
（兰州军区兰州总医院：1.心血管内科，2.医务部，甘肃 兰州 730050）
Author(s):
CHEN Yong-qing1;  CAI Xiao-qing1;  HU Wei1;  WEN Jin2
(1.Department of Cardiology, 2.Department of Medical Administration, Lanzhou General Hospital, Lanzhou Military Command, Lanzhou 730050, Gansu, China)
关键词:
左西孟旦; 心力衰竭; 心源性休克; 心肌梗死; 感染性休克
Keywords:
levosimendan;  congestive heart failure;  cardiogenic shock;  myocardial infarction;  septic shock
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
左西孟旦是新近研发的一种钙离子增敏剂，通过发挥独立于β-肾上腺素能的强心作用而治疗失代偿期心力衰竭（HF），在一些难治性HF治疗中疗效明显。现有证据表明左西孟旦在心源性休克，心脏围手术期和感染性休克等心血管危重症患者治疗中是安全有效的，能显著减少患者死亡率。但上述结论仍有待进一步随机对照研究（RCT）证实。
Abstract:
Levosimendan, a calcium sensitizer aimed at treating decompensated or refractory heart failure, exerts its positive inotropic effects independently of beta adrenergic receptor in cases of severe and intractable heart failure. Available evidences supports the concept that levosimendan is a safe and valid option in treating critically ill cardiovascular patients. Additional data from well-designed randomized prospective controlled trials in critically ill patients is warranted to appreciate the therapeutic role or roles for levosimendan in critically ill cardiovascular pateints.

参考文献/References

[1]Tacon CL McCaffrey J,Delaney A.Dobutamine for pa-tients with severe heart failure:a systematic review and meta-analysis of randomised controlled trials[J].Intensive Care Med,2012,38(3):359-367.

[2]Landoni G,Mizzi A,Biondi-Zoccai G,et al.Levosimendan re-duces mortality in critically ill patients. A meta-analysis of randomized controlled studies[J].Minerva Anestesiol,2010,76(4):276-286.

[3]Givertz MM,Andreou C,Conrad CH,et al.Di-rect myocardial effects of levosimendan in humans with left ventricular dysfunction:alteration of force-frequen-cy and relaxation-frequency relationships[J].Circulation,2007,115(10):1218-1224.

[4]Haikala H,Nissinen E,Etemadzadeh E,et al.Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation[J].J Cardiovasc Pharmacol,1995,25(5):794-801.

[5]Latva-Hirvela J,Kyto V,Saraste A,et al.Effects of levosimendan in experimen-tal acute coxsackievirus myocarditis[J].Eur J Clin Invest,2009,39(10):876-882.

[6]Follath F,Cleland JG,Just H,et al.Efficacy and safety of intrave-nous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study):a randomised double-blind trial[J].Lancet,2002,360(9328):196-202.

[7]Morelli A,Donati A,Ertmer C,et al.Levosimendan for re-suscitating the microcirculation in patients with sep-tic shock:a randomized controlled study[J].Crit Care,2010,14(6):R232.

[8]Mebazaa A,Nieminen MS,Packer M,et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure:the SURVIVE Randomized Trial[J].JAMA,2007,297(17):1883-1891.

[9]Nanas JN,Papazoglou PP,Terrovitis JV,et al.Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone[J].Am J Cardiol,2004,94(10):1329-1332.

[10]Al-Shawaf E,Ayed A,Vislocky I,et al.Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery[J].J Cardiothorac Vasc Anesth,2006,20(3):353-357.

[11]Fuhrmann JT,Schmeisser A,Schulze MR,et al.Levo-simendan is superior to enoximone in refractory cardio-genic shock complicating acute myocardial infarction[J].Crit Care Med,2008,36(8):2257-2266.

[12]Bocchi EA,Vilas-Boas F,Moreira Mda C,et al.Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort.Results of the BELIEF study[J].Arq Bras Cardiol,2008,90(3):182-190.

[13]Omerovic E,Ramunddal T,Albertsson P,et al.Levosimendan neither improves nor worsens mortality in patients with cardio-genic shock due to ST-elevation myocardial infarction[J].Vasc Health Risk Manag,2010,6:657-663.

[14]Kerbaul F,Rondelet B,Demester JP,et al.Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure[J].Crit Care Med,2006,34(11):2814-2819.

[15]Russ MA,Prondzinsky R,Carter JM,et al.Right ventricular function in myocardial infarction complicated by cardiogenic shock:Improvement with levosimendan[J].Crit Care Med,2009,37(12):3017-3023.

[16]Braun JP,Schneider M,Dohmen P,et al.Successful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support[J].J Cardiothorac Vasc Anesth,2004,18(6):772-774.

[17]Raja SG,Rayen BS.Levosimendan in cardiac surgery:current best available evidence[J].Ann Thorac Surg,2006,81(4):1536-1546.

[18]Levin RL,Degrange MA,Porcile R,et al.[The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome][J].Rev Esp Cardiol,2008,61(5):471-479.

[19]Beiras-Fernandez A,Kur F, Kaczmarek I,et al.Levosimendan for primary graft failure after heart transplantation:a 3-year follow-up[J].Transplant Proc,2011,43(6):2260-2262.

[20]Eriksson HI,Jalonen JR,Heikkinen LO,et al.Levosimendan facilitates weaning from cardiopulmonary bypass in pa-tients undergoing coronary artery bypass grafting with impaired left ventricular function[J].Ann Thorac Surg,2009,87(2):448-454.

[21]Lomivorotov VV,Cherniavskiy AM,Boboshko VA,et al.Levosimen-dan vs. intra-aortic balloon pump in high-risk cardiac surgery[J].Asian Cardiovasc Thorac Ann,2011,19(2):154-159.

[22]Kolseth SM,Nordhaug DO,Stenseth R,et al.Prophylactic treatment with levosimendan:a retrospective matched-control study of patients with reduced left ventricular function[J].Eur J Cardiothorac Surg,2009,36(6):1024-1030.

[23]Jarvela K,Maaranen P,Sisto T,Ruokonen E.Levosi-mendan in aortic valve surgery:cardiac performance and recovery[J].J Cardiothorac Vasc Anesth,2008,22(5):693-698.

[24]Lahtinen P,Pitkanen O,Polonen P,et al.Levosimendan reduces heart failure after cardiac surgery:a prospective,randomized, place-bo-controlled trial[J].Crit Care Med,2011,39(10):2263-2270.

[25]Morelli A,Teboul JL,Maggiore SM,et al.Effects of levo-simendan on right ventricular afterload in patients with acute respiratory distress syndrome:a pilot study[J].Crit Care Med,2006,34(9):2287-2293.

[26]Morelli A,De Castro S,Teboul JL,et al.Effects of levosimendan on systemic and regional hemodynamics in septic myocar-dial depression[J].Intensive Care Med,2005,31(5):638-644.

备注/Memo

备注/Memo:
收稿日期：2016-11-25.基金项目：军队保健专项课题资助（14BJZ25） 通讯作者：陈永清，主任医师，主要从事心血管病研究 Email：chyqmd@163.com
更新日期/Last Update: 1900-01-01